Skip to main content

Table 2 Un-weighted and IPT-weighted Kaplan-Meier and competing risk of any urinary adverse event

From: Inverse probability of treatment-weighted competing risks analysis: an application on long-term risk of urinary adverse events after prostate cancer treatments

 

Control

EBRT

BT

BT + EBRT

RP

RP + EBRT

Cryotherapy

Subjects (n)

144,816

44,318

14,259

11,835

26,790

1557

2115

Un-weighted KMa

       

Event rate (n per 100 person-yr)

1.78

2.40

2.70

3.91

4.02

6.08

3.71

KM 10-yr. cumulative incidence (%)

16.1

19.7

19.8

28.4

26.6

37.8

23.4

IPT-weighted KMa

       

KM 10-yr. cumulative incidence (%)

17.0

17.6

20.0

27.4

27.2

36.4

19.4

HRb

1

1.114

1.428

1.969

2.442

3.194

1.56

95% CI

 

1.07, 1.16

1.33, 1.53

1.85, 2.10

2.34, 2.55

2.79, 3.66

1.30, 1.87

Un-weighted CR

       

KM 10-yr. cumulative incidence (%)

12.1

16.4

18.1

25.8

25.6

36.2

22.4

HRc

1

1.430

1.660

2.416

2.835

4.057

2.082

95% CI

 

1.38, 1.48

1.58, 1.74

2.31, 2.53

2.75, 2.93

3.70, 4.46

1.85, 2.35

IPT-weighted CR

       

KM 10-yr. cumulative incidence (%)

12.7

14.8

18.3

25.2

26.0

36.5

22.1

HRd

1

1.194

1.585

2.214

2.761

3.655

1.754

95% CI

 

1.15, 1.24

1.50, 1.67

2.11, 2.32

2.67, 2.86

3.28, 4.07

1.54, 1.99

  1. Abbreviations: EBRT external beam radiotherapy, BT brachytherapy, RP radical prostatectomy, UAE urinary adverse event, KM Kaplan-Meier, CR competing risks, HR hazard ratio, CI confidence interval
  2. aResults from the Jarosek et al. paper for un-weighted KM and IPT-weighted KM models
  3. bCox proportional hazard model with inverse probability weighting
  4. cCompeting risks analysis model
  5. dCompeting risks analysis model with inverse probability of treatment weighting